Cited 17 times in
Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 유승찬 | - |
dc.date.accessioned | 2022-12-22T02:00:30Z | - |
dc.date.available | 2022-12-22T02:00:30Z | - |
dc.date.issued | 2022-05 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/191415 | - |
dc.description.abstract | Background: Statin treatment increases the risk of new-onset diabetes mellitus (NODM); however, data directly comparing the risk of NODM among individual statins is limited. We compared the risk of NODM between patients using pitavastatin and atorvastatin or rosuvastatin using reliable, large-scale data. Methods: Data of electronic health records from ten hospitals converted to the Observational Medical Outcomes Partnership Common Data Model (n = 14,605,368 patients) were used to identify new users of pitavastatin, atorvastatin, or rosuvastatin (atorvastatin + rosuvastatin) for ≥ 180 days without a previous history of diabetes or HbA1c level ≥ 5.7%. We conducted a cohort study using Cox regression analysis to examine the hazard ratio (HR) of NODM after propensity score matching (PSM) and then performed an aggregate meta-analysis of the HR. Results: After 1:2 PSM, 10,238 new pitavastatin users (15,998 person-years of follow-up) and 18,605 atorvastatin + rosuvastatin users (33,477 person-years of follow-up) were pooled from 10 databases. The meta-analysis of the HRs demonstrated that pitavastatin resulted in a significantly reduced risk of NODM than atorvastatin + rosuvastatin (HR 0.72; 95% CI 0.59-0.87). In sub-analysis, pitavastatin was associated with a lower risk of NODM than atorvastatin or rosuvastatin after 1:1 PSM (HR 0.69; CI 0.54-0.88 and HR 0.74; CI 0.55-0.99, respectively). A consistently low risk of NODM in pitavastatin users was observed when compared with low-to-moderate-intensity atorvastatin + rosuvastatin users (HR 0.78; CI 0.62-0.98). Conclusions: In this retrospective, multicenter active-comparator, new-user, cohort study, pitavastatin reduced the risk of NODM compared with atorvastatin or rosuvastatin. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | BioMed Central | - |
dc.relation.isPartOf | CARDIOVASCULAR DIABETOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Atorvastatin / adverse effects | - |
dc.subject.MESH | Cohort Studies | - |
dc.subject.MESH | Diabetes Mellitus* / diagnosis | - |
dc.subject.MESH | Diabetes Mellitus* / drug therapy | - |
dc.subject.MESH | Diabetes Mellitus* / epidemiology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects | - |
dc.subject.MESH | Multicenter Studies as Topic | - |
dc.subject.MESH | Quinolines | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Rosuvastatin Calcium / adverse effects | - |
dc.title | Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Biomedical Systems Informatics (의생명시스템정보학교실) | - |
dc.contributor.googleauthor | Won-Woo Seo | - |
dc.contributor.googleauthor | Seung In Seo | - |
dc.contributor.googleauthor | Yerim Kim | - |
dc.contributor.googleauthor | Jong Jin Yoo | - |
dc.contributor.googleauthor | Woon Geon Shin | - |
dc.contributor.googleauthor | Jinseob Kim | - |
dc.contributor.googleauthor | Seng Chan You | - |
dc.contributor.googleauthor | Rae Woong Park | - |
dc.contributor.googleauthor | Young Min Park | - |
dc.contributor.googleauthor | Kyung-Jin Kim | - |
dc.contributor.googleauthor | Sang Youl Rhee | - |
dc.contributor.googleauthor | Meeyoung Park | - |
dc.contributor.googleauthor | Eun-Sun Jin | - |
dc.contributor.googleauthor | Sung Eun Kim | - |
dc.identifier.doi | 10.1186/s12933-022-01524-6 | - |
dc.contributor.localId | A02478 | - |
dc.relation.journalcode | J00460 | - |
dc.identifier.eissn | 1475-2840 | - |
dc.identifier.pmid | 35606846 | - |
dc.subject.keyword | Common data model | - |
dc.subject.keyword | Diabetes mellitus | - |
dc.subject.keyword | Pitavastatin | - |
dc.subject.keyword | Statin | - |
dc.contributor.alternativeName | You, Seng Chan | - |
dc.contributor.affiliatedAuthor | 유승찬 | - |
dc.citation.volume | 21 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 82 | - |
dc.identifier.bibliographicCitation | CARDIOVASCULAR DIABETOLOGY, Vol.21(1) : 82, 2022-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.